Summary:
Patients with COVID-19 who are immunocompromised are at increased risk of progressing to severe illness due to prolonged infection, limited contribution by the immune system in clearing the infection, and increased potential for viral resistance. The purpose of the study is to evaluate the study medication in the treatment of COVID-19 in participants who are immunocompromised.
Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:
- Age 12 and older
- Confirmed SARS-CoV-2 (Covid-19) infection within 5 days prior
- Immunocompromised
Qualified Participants May Receive:
Compensation package includes:
$150 for each visit to study site
All study medication, assessments and examinations are free to the participants.